^{The Augustine Therapeutics pipeline is based on a novel generation of small molecule inhibitors of HDAC6, a validated molecular target with strong biological rational for neuromuscular and neurodegenerative disorders, and high therapeutic potential in other cardiometabolism, inflammatory and autoimmune diseases.} 

We currently have three programs in development.

Our most advanced asset is at the regulatory non clinical developement stage. AGT100216 is the first clinical candidate, acting as a peripherally-restricted, orally bioavailable and selective HDAC6i for the treatment of Charcot-Marie-Tooth (CMT) disease with therapeutic application in other type of axonopathies such as Chemotherapy-induced peripheral neuropathy (CIPN). 

Our second program is focusing on brain penetrant, orally bioavailable and selective HDAC6i,  currently in lead optimization stage, for the treatment of neurodegenerative diseases, such as Amyotrophic lateral sclerosis or Frontotemporal dementia.

Our third program is a novel class of peripherally-restricted, orally bioavailable and selective HDAC6i for the treatment of cardio-metabolism diseases, currently in lead optimization stage.

With a "Pipeline-in-a-product" approach, our drug discovery engine is poised to deliver multiple drug candidates with peripheral or central actions.